Short seller Scorpion Capital disclosed a short position in TransMedics Group Inc (NASDAQ:TMDX) accusing the organ transplant ...

Shares of TransMedics Group (NASDAQ: TMDX) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came ...

Shares of TransMedics (TMDX) are falling after Scorpion Capital revealed its short position on the company Friday. The ...

EST TransMedics (TMDX) down 10% to $65.39 after Scorpion Capital short reportStay Ahead of the Market:Discover outperforming stocks and ...

The report further alleges that TransMedics has been involved in kickbacks, billing fraud, unreported device failures, and ...

Scorpion Capital said in a newly-issued short report that in “20 years of shorting, TransMedics (TMDX) is the most extreme and grotesque ...

NDAQ:TMDX) Kehoe Law Firm, P.C. Securities Investigation on Behalf of Investors of TransMedics Group Stock Following Critical Report - NASDAQ: TMDX ...

Eli Lilly in talks to acquire cancer biotech Scorpion Therapeutics for $2.5 billion, with potential milestone payments.

Transmedics replaced its CFO in early December. Management also narrowed fourth-quarter guidance to the lower half of the previous range. Can Transmedics reaccelerate growth after this slowdown ...

TransMedics is a top dog and first mover in an important industry, but it sold off heavily after earnings. Despite the sell-off, the company has numerous growth drivers that make it compelling ...

TransMedics is transforming organ transplants with advanced technology and integrated logistics. Strong market demand and expanding adoption support long-term growth potential despite the recent ...

JPMorgan analyst Allen Gong downgraded TransMedics (TMDX) to Neutral from Overweight with a price target of $75, down from $116. The company’s near-term outlook “remains less certain” as ...